查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790408

Eliquis（Apixaban）市場規模、佔有率和趨勢分析報告：按適應症、分銷管道、地區和細分市場預測，2025 年至 2033 年

Eliquis (Apixaban) Market Size, Share & Trends Analysis Report By Indication (Atrial Fibrillation (AF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

Eliquis（Apixaban）市場摘要

2024 年全球 Eliquis（Apixaban）市值估計為 207 億美元，預計到 2033 年將達到 188.7 億美元，2025 年至 2033 年的複合年成長率為 -2.2%。這一成長主要受專利獨佔權的喪失、學名藥競爭加劇以及主要市場價格下降的推動。

全球心房顫動 (AF) 和靜脈血栓栓塞症(VTE) 負擔日益加重，已成為 Eliquis（Apixaban）市場的主要驅動力。由於 AF 顯著增加中風風險，使用抗凝血劑進行長期預防的現象正在增加。 2022 年 6 月，《臨床醫學雜誌》發表了統合分析，評估了Apixaban的安全性和有效性。研究發現，與其他抗凝血劑相比，Apixaban表現出良好的療效，中風、死亡和大出血風險較低。 Eliquis 良好的安全性和最低的監測要求使其成為首選。循環系統實踐指南擴大了直介面服抗凝血劑的使用，導致其在基層醫療和專科護理中廣泛應用。隨著 AF 和 VTE 病例的增加，尤其是在老化人口中，對像 Eliquis 這樣可靠、易於管理的抗凝血劑的需求持續成長。

臨床實務向直介面服抗凝血劑的轉變正在鞏固 Eliquis 的市場地位。醫療保健提供者重視直介面服抗凝血劑 (DOAC)，因為其藥物動力學可預測、劑量固定，且與Warfarin相比，發生嚴重出血事件的風險較低。 Eliquis 在大型試驗中表現出色，並有助於提高全球處方率。患者受益於簡化的治療方法，可提高依從性並減少就診次數。隨著從傳統抗凝血劑向 DOAC 的轉變加速，Eliquis 已做好準備，擴大其在全球抗凝血劑市場的佔有率。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章 Eliquis（Apixaban）市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章 Eliquis（Apixaban）市場：適應症業務分析

  • 2024年及2033年指示市場佔有率
  • 指示細分儀表板
  • 市場規模、預測與趨勢分析（按適應症，2021-2033 年）
  • 心房顫動（AF）
  • 深層靜脈栓塞症（DVT）
  • 肺動脈栓塞（PE）
  • 術後靜脈血栓栓塞症（VTE）預防
  • 其他

第5章 Eliquis（Apixaban）市場：分銷通路業務分析

  • 2024年及2033年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 市場規模、預測與趨勢分析（按分銷管道，2021-2033 年）
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第6章 Eliquis（Apixaban）市場：區域估計與趨勢分析

  • 2024 年及 2033 年區域市場佔有率分析
  • 區域市場儀表板
  • 2021-2033年市場規模與預測趨勢分析
  • 北美洲
    • 按國家/地區，2021-2033 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • F. Hoffmann-La Roche Ltd.
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Pfizer Inc.
    • GSK plc
    • Novartis AG
    • AstraZeneca
    • Johnson &Johnson Private Limited
    • Bristol-Myers Squibb Company
Product Code: GVR-4-68040-673-0

Eliquis (Apixaban) Market Summary

The global Eliquis (apixaban) market size was estimated at USD 20.70 billion in 2024 and is projected to reach USD 18.87 billion by 2033, with a decline of CAGR of -2.2% from 2025 to 2033, primarily due to loss of patent exclusivity, growing generic competition, and consequent price erosion across major markets.

The increasing global burden of atrial fibrillation (AF) and venous thromboembolism (VTE) has emerged as a major driver for the Eliquis (Apixaban) market. AF significantly raises the risk of stroke, prompting greater use of anticoagulants for long-term prevention. In June 2022, the Journal of Clinical Medicine published a meta-analysis of over 3.9 million adults with atrial fibrillation, assessing apixaban's safety and effectiveness. The study found that apixaban had favorable outcomes compared to other anticoagulants, with lower stroke risks, mortality, and major bleeding. Eliquis has become a preferred option due to its favorable safety profile and minimal need for monitoring. Clinical guidelines in cardiology have expanded the use of direct oral anticoagulants, leading to broader adoption across primary and specialty care. As AF and VTE cases rise, particularly among aging populations, the demand for reliable and easy-to-administer anticoagulants such as Eliquis continues to grow.

Shifts in clinical practice toward direct oral anticoagulants have strengthened Eliquis's market position. Healthcare providers value DOACs for their predictable pharmacokinetics, fixed dosing, and lower risk of major bleeding events than warfarin. Eliquis has shown superior results in large-scale trials, contributing to its high prescription rates worldwide. Patients benefit from simplified treatment regimens that improve adherence and reduce healthcare visits. As transitioning from traditional anticoagulants to DOACs accelerates, Eliquis is well-positioned to capture a growing share of the global anticoagulant market.

Global Eliquis (Apixaban) Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Eliquis (apixaban) market report based on indication, distribution channel, and region:

  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Atrial Fibrillation (AF)
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Post-Operative Venous Thromboembolism (VTE) Prophylaxis
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Eliquis (Apixaban) Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Eliquis (Apixaban) Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2033
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 4.4. Atrial Fibrillation (AF)
    • 4.4.1. Atrial Fibrillation (AF) Market, 2021 - 2033 (USD Million)
  • 4.5. Deep Vein Thrombosis (DVT)
    • 4.5.1. Deep Vein Thrombosis (DVT) Market, 2021 - 2033 (USD Million)
  • 4.6. Pulmonary Embolism (PE)
    • 4.6.1. Pulmonary Embolism (PE) Market, 2021 - 2033 (USD Million)
  • 4.7. Post-Operative Venous Thromboembolism (VTE) Prophylaxis
    • 4.7.1. Post-Operative Venous Thromboembolism (VTE) Prophylaxis Market, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Eliquis (Apixaban) Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.6. Online Pharmacies
    • 5.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 6. Eliquis (Apixaban) Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Eliquis (Apixaban) Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Distribution Channel Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Distribution Channel Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Distribution Channel Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Distribution Channel Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Distribution Channel Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Distribution Channel Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Distribution Channel Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Distribution Channel Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Distribution Channel Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Distribution Channel Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Distribution Channel Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Distribution Channel Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Distribution Channel Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Distribution Channel Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Distribution Channel Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Distribution Channel Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Distribution Channel Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Distribution Channel Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Distribution Channel Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Distribution Channel Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Distribution Channel Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Distribution Channel Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Distribution Channel Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. F. Hoffmann-La Roche Ltd.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Mylan NV
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Teva Pharmaceutical Industries Ltd.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Sanofi
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Pfizer Inc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. GSK plc
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Novartis AG
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. AstraZeneca
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Johnson & Johnson Private Limited
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Bristol-Myers Squibb Company
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Eliquis (apixaban) market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 5 Global Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6 North America Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 8 North America Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9 U.S. Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 10 U.S. Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 Canada Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 12 Canada Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 Mexico Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 14 Mexico Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15 Europe Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 17 Europe Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18 UK Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 19 UK Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Germany Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 21 Germany Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22 France Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 23 France Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 Italy Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 25 Italy Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26 Spain Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 27 Spain Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28 Norway Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 29 Norway Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 Denmark Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 31 Denmark Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32 Sweden Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 33 Sweden Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific Eliquis (apixaban) market, by indication, 2021 - 2033 (USD
  • Table 36 Asia Pacific Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37 Japan Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 38 Japan Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 China Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 40 China Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41 India Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 42 India Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43 Australia Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 44 Australia Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 South Korea Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 46 South Korea Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47 Thailand Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 48 Thailand Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49 Latin America Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 51 Latin America Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Brazil Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 53 Brazil Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Argentina Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 55 Argentina Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59 South Africa Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 60 South Africa Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63 UAE Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 64 UAE Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65 Kuwait Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
  • Table 66 Kuwait Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Eliquis (apixaban) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Eliquis (apixaban) market dynamics
  • Fig. 12 Eliquis (apixaban) market: Porter's five forces analysis
  • Fig. 13 Eliquis (apixaban) market: PESTLE analysis
  • Fig. 14 Indication market, 2021 - 2033 (USD Million)
  • Fig. 15 Atrial Fibrillation (AF) market, 2021 - 2033 (USD Million)
  • Fig. 16 Deep Vein Thrombosis (DVT) market, 2021 - 2033 (USD Million)
  • Fig. 17 Pulmonary Embolism (PE) market, 2021 - 2033 (USD Million)
  • Fig. 18 Post-Operative Venous Thromboembolism (VTE) Prophylaxis market, 2021 - 2033 (USD Million)
  • Fig. 19 Others market, 2021 - 2033 (USD Million)
  • Fig. 20 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 21 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 22 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 23 Online Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 24 Eliquis (apixaban) market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 North America Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 33 Europe Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 50 Asia Pacific Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 63 Latin America Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 68 MEA Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait Eliquis (apixaban) market, 2021 - 2033 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis
  • Fig. 79 Strategic framework